Incyte (Nasdaq: INCY) shares tested a descending trendline within a consolidation pattern on Friday as investors awaited further updates on the company's drug pipeline. Jakafi, Incyte's leading product, is expected to face patent expiry in 2028, putting roughly $3.4 billion in annual sales at risk and making replacement revenue from newer programs a central focus for the market.
As of 12:08 p.m. Eastern time on Sept. 18, Incyte shares were trading at $127.96, up $0.34, or 0.27%. The quote was not real-time. The stock had rebounded from support near its 50-day moving average and was trading within a cup-and-handle consolidation pattern. The pattern's key level is viewed at $130.80, while the shares were also testing the declining trendline formed across the handle.
Jakafi remains the revenue anchor ahead of 2028 expiry
Incyte's best-known product is Jakafi, which is used to treat graft-versus-host disease, myelofibrosis and polycythemia vera, two blood cancers. The company also markets Opzelura, a topical cream for eczema and vitiligo.
Jakafi remains Incyte's largest source of revenue. Sales reached $3.09 billion last year, up nearly 11% and slightly above the market expectation of $3.06 billion. Analysts expect sales to peak at about $3.37 billion in 2028 before falling to $1.14 billion, $728 million and $886 million in the following three years.
RBC Capital Markets analyst Brian Abrahams said Incyte's previous efforts to build a pipeline capable of offsetting the potential revenue gap had progressed unevenly. The scale and timing of the decline after Jakafi's patent expiry will depend on the pace of new product launches, clinical data and the development of competing treatments.
Early antibody program targets three blood cancers
Clinical-trial registration information shows that Incyte is conducting an early-stage study of INCA036978, an antibody drug about which the company has previously disclosed limited information. The program is in Phase 1 development for myeloproliferative neoplasms and is being tested both as a standalone treatment and in combination with standard therapy.
The trial covers three major myeloproliferative neoplasms: myelofibrosis, polycythemia vera and essential thrombocythemia. Abrahams said the breadth of the program could indicate that the drug is not limited to a single genetic target. If later clinical results support that approach, its potential patient population could be materially larger than that of another program, INCA033989. At this stage, however, there is not enough data to establish its efficacy or safety.
INCA033989 is focused primarily on patients with essential thrombocythemia and myelofibrosis and works through a mechanism involving the CALR gene. Different CALR mutations may require different doses, leaving questions around dose selection and efficacy validation. Incyte has also discontinued programs targeting BET and ALK2 in blood disorders.
ESMO may provide an update on the KRAS program
Beyond the risks surrounding Jakafi, investors are waiting to see which research programs Incyte will present at the European Society for Medical Oncology, or ESMO, meeting in October. The company may provide updated data on the KRAS inhibitor INCB161734 in pancreatic cancer and other solid tumors.
The company disclosed only a limited amount of related data in the first quarter, leaving too little evidence for a firm conclusion. KRAS has long been considered difficult to target directly because its structure lacks an obvious binding site for antibodies. In recent years, however, several biotechnology companies have made progress in developing drugs against the target, keeping clinical results in the area under close observation.
Based on public data, Abrahams estimates that INCB161734 combined with chemotherapy could produce an objective response rate of 62.5% and a disease control rate of 95.8% in pancreatic cancer. Those figures are similar to the results targeted by a competing therapy being tested by Revolution Medicines (Nasdaq: RVMD), although the actual performance of Incyte's program will depend on subsequent clinical disclosures.
William Blair analyst Matt Phipps said Incyte also plans to present data at ESMO from its colorectal cancer program and other solid-tumor projects. He rates the stock "Market Perform." Abrahams has a "Hold" rating and raised his price target to $109 earlier this week.
Technical signals put the stock near the upper end of its range
MarketSurge data show that Incyte shares are above their major moving averages, with $130.80 marking the key level in the cup-and-handle pattern. A break above the handle's descending trendline could make Friday's intraday high of $128.72 another short-term reference point, although such technical signals do not establish that the company's fundamentals have improved.
On the weekly chart, Incyte's relative strength line has produced a blue dot, indicating that the measure reached a new high while the stock was consolidating or attempting a breakout. The shares have a Relative Strength Rating of 91, placing their 12-month performance in the top 9% of all stocks. Their Composite Rating is 99, indicating a score above 99% of stocks within the relevant fundamental and technical ranking system.
For investors assessing Incyte, the key facts are the timing of revenue pressure after Jakafi's patent expiry, early clinical results for INCA036978 and data for the KRAS inhibitor INCB161734 at ESMO. Together, those updates will shape the market's assessment of whether the pipeline can offset the expected decline in Jakafi sales.